Lomustine (CCNU)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LOMUSTINE |
|---|---|
| Type | Drug |
| Aliases | CCNUCeeNULomustineЛомустин |
| Status | reviewed 2026-05-08 |
| Diseases | DIS-GLIOMA-LOW-GRADE |
| Sources | None declared |
Drug Facts
| Class | Alkylating agent (nitrosourea) |
|---|---|
| Mechanism | DNA alkylation and cross-linking; crosses blood-brain barrier; myelosuppressive |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-09 |
Warnings
- Severe bone marrow suppression — do not administer more frequently than every 6 weeks
Notes
STUB — minimal entry to satisfy FK reference from REG-RT-PCV-LGG. Requires clinical signoff before publication.
Used By
Regimens
REG-RT-PCV-LGG- Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma